Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses - Kelley, R K; Abou-Alfa, G K; Bendell, J C (J Clin Oncol, 2017)
(15, Suppl):